Abstract
Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Current Drug Safety
Title: Pain-Relief Medication and Risk of Fractures
Volume: 3 Issue: 3
Author(s): Peter Vestergaard
Affiliation:
Keywords: Pain-Relief Medication, Fractures, analgesics, opiate, prostaglandin system, non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid, acetaminophen
Abstract: Medications to treat pain are in widespread use and any change in the risk of fracture may consequently have a significant impact at a population level. Strong analgesics of the opiate and opiate-like group are associated with an increased risk of fractures probably from an increased risk of falls resulting from the dizziness induced by these drugs. However, not all strong analgesics are associated with an increased risk of fractures. The differences are not readily explained from variations in pharmacokinetic properties. Weak analgesics mainly interact with the prostaglandin system; these drugs include non-steroidal anti-inflammatory drugs (NSAIDs), acetylsalicylic acid and acetaminophen. Acetaminophen is associated with an increased risk of fractures while acetylsalicylic acid is not. Some but not all NSAIDs are associated with an increased fracture risk, and the differences are not explained by variations in pharmacokinetic properties. More research is needed to determine if some analgesics are safer than others with respect to fracture risk.
Export Options
About this article
Cite this article as:
Vestergaard Peter, Pain-Relief Medication and Risk of Fractures, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699504
DOI https://dx.doi.org/10.2174/157488608785699504 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Assessing Depression in Patients with an Acute Coronary Syndrome: A Literature Review
Current Psychiatry Reviews The Coronary Artery Risk Detection in Appalachian Communities (CARDIAC) Project: An 18 Year Review
Current Pediatric Reviews Intervention for Cardiac Repair: A Clinical Perspective
Current Stem Cell Research & Therapy Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry Transbronchial Needle Aspiration (TBNA): Past Present and Future
Current Respiratory Medicine Reviews Anacetrapib: A New Weapon Against Dyslipidemia
Current Clinical Pharmacology Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial
Endocrine, Metabolic & Immune Disorders - Drug Targets Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Rashes, Sniffles, and Stroke: A Role for Infection in Ischemic Stroke of Childhood
Infectious Disorders - Drug Targets ErbB4 and its Isoforms: Patentable Drug Targets?
Recent Patents on DNA & Gene Sequences Heart Failure in Acute Ischemic Stroke
Current Cardiology Reviews Psychological Stress in Pathogenesis of Essential Hypertension
Current Hypertension Reviews Eltrombopag Induced Thrombosis: A Case with Acute Myocardial Infarction
Current Drug Safety Intra-uterine Growth Retardation as a Risk Factor of Postnatal Metabolic Disorders
Current Pharmaceutical Biotechnology The Impact of Dietary Habits and Nutritional Deficiencies in Urban African Patients Living with Heart Failure in Soweto, South Africa – A Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Increased Risk of Cardiovascular Complications in Chronic Kidney Disease: A Possible Role of Leptin
Current Pharmaceutical Design Pleiotropic Effects of Statins - Clinical Evidence
Current Pharmaceutical Design microRNAs in Cancer: Lessons from Melanoma
Current Pharmaceutical Design